vTv Therapeutics (NASDAQ:VTVT – Get Free Report) is expected to be announcing its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter.
vTv Therapeutics Price Performance
VTVT stock opened at $14.85 on Friday. The company has a market cap of $47.37 million, a P/E ratio of -3.28 and a beta of 1.07. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $30.99. The firm has a 50-day moving average of $16.47 and a 200 day moving average of $15.31.
Analyst Ratings Changes
A number of research firms have recently commented on VTVT. Alliance Global Partners began coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock. StockNews.com started coverage on shares of vTv Therapeutics in a research report on Tuesday, March 11th. They set a “sell” rating on the stock.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
- Five stocks we like better than vTv Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is a Dividend King?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.